

Fig S5. Loss of BTK function leads to decreased ATM levels. **A,** Cell viability of MCL cell lines following 72-hr treatment with BGB-3111. Drug concentrations are as follows: 0.03, 0.1, 0.3, 1, 3, 10, and 30 μM. Luminescence was quantified by Cell TiterGlo Reagent and presented as the mean ± SD of triplicate values. **B,** Total ATM and phospho-ATM levels in BTK knockdown mutants (BTK KD1 and KD2), Jeko and Jeko R cells. **C,** Total ATM and phospho-ATM levels in Jeko, Jeko R and BTK KD2 cells upon 3 hr-treatment with BGB-3111. **D,** Total ATM and its downstream components such as p53, P21, p-AMPK, BAX, and BCL-2 in Jeko and Mino cells upon 3 hr-treatment with BGB-3111. GAPDH was used as a loading control.